Which statement best describes CKD's effect on osteoporosis management?

• A. CKD alters mineral metabolism and bone turnover; use CKD-appropriate targets, avoid certain medications, coordinate with nephrology; treat CKD-MBD risk
• B. CKD has no impact on osteoporosis management
• C. CKD only affects calcium but not phosphate
• D. CKD requires dialysis before treating osteoporosis

Answer: (A)

CKD changes how minerals are handled and how bone remodels, creating CKD-related mineral and bone disorder. When managing osteoporosis in someone with CKD, you must aim for targets that reflect this altered physiology rather than standard osteoporosis targets. In CKD, phosphate tends to accumulate, vitamin D activation declines, and secondary hyperparathyroidism can drive abnormal bone turnover. That means treatment plans should address CKD-appropriate calcium, phosphate, and PTH levels, adjust vitamin D therapy as kidney function changes, and consider bone turnover status when selecting therapies. Some osteoporosis medications may be less safe or require special considerations in CKD, so coordinating with nephrology helps tailor care and monitor risks like vascular calcification or adynamic bone disease. You don’t have to wait for dialysis to start addressing CKD-related bone issues, and it’s not only about calcium or about dialysis being required first. The essential idea is that CKD alters mineral metabolism and bone turnover, so osteoporosis management must be CKD-aware and multidisciplinary.